All In Biotech

Drug Trial Radar · NCT04928287

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease"

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jun 28, 2021

Primary completion

Feb 6, 2023

Study completion Feb 6, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease. The trial includes a screening period of up to 4 weeks, a 32-week treatment period, and a safety Follow-up period of 20 weeks after the last investigational product administration. This clinical trial will be open to enroll 24 eligible participants diagnosed with Parkinson's disease. Patients' recruitment will be conducted by the study team, if eligible participants are identified based on eligibility criteria, a screening visit will be scheduled. Informed consent form will be given to the study participants and signed before any study procedures. Informed consent form will include information about the clinical trial and some aspects should be considered during this process.

Conditions

  • Parkinson Disease

Interventions

  • HB-adMSCsBiological

    HB-adMSCs will be administered intravenously to study participants who qualify.

  • PlaceboOther

    Placebo will be administered intravenously to study participants who qualify.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in MDS-UPDRS Part II.Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52
  2. Laboratory Values. CBC (% of WBC)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  3. Laboratory Values. CBC (10^9 Cells/L)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  4. Laboratory Values. CBC (10^12 Cells/L)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  5. Laboratory Values. CBC (pg)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  6. Laboratory Values. CBC (fL)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  7. Laboratory Values. CBC (g/dL)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  8. Laboratory Values. CBC (% Difference in Volume and Size of RBC)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  9. Laboratory Values. CBC (% of Total Blood Cell Count)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  10. Vital Signs. - Blood Pressure (mmHg)Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52
  11. Weight in kg.Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52
  12. Laboratory Values. CMP (mg/dL)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  13. Laboratory Values. CMP (g/dL)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  14. Laboratory Values. CMP (IU/L)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  15. Laboratory Values. CMP (mL/Min/1.73m^2)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  16. Laboratory Values. CMP (mmol/L)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  17. Laboratory Values. CMP (Ratio: Albumin (g/dL) to Calc. Globulin (g/dL))Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  18. Laboratory Values. CMP (Ratio: Urea Nitrogen (mg/dL) to Creatinine (mg/dL))Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  19. Laboratory Values. Coagulation Panel (Seconds)Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  20. Laboratory Values. Coagulation Panel (Ratio: Prothrombin Time (Seconds) / Mean Normal Prothrombin Time (Seconds))Time frame: Baseline (Week 0), Week 24, and End of Study (Week 52)
  21. Vital Signs. - Respiratory Rate (Breaths Per Minute)Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52
  22. Vital Signs. - Heart Rate (Beats Per Minute)Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52
  23. Vital Signs. - Body Temperature (Celsius )Time frame: Baseline through Week 32, Follow-up at week 42 and End of Study at week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hope Biosciences Stem Cell Research Foundation

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.